Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC

Date
2020
Author
Jassem, Jacek
Komatsubara, Kimberly
Deng, Yu
Kuriki, Hiroshi
Wen, Xiaohui
McCleland, Mark
Mocci, Simonetta
Herbst, Roy S.
Spigel, David R.
Giaccone, Giuseppe
de Marinis, Filippo
Reinmuth, Niels
Vergnenegre, Alain
Barrios, Carlos H.
Morise, Masahiro
Felip, Enriqueta
Andric, Zoran
Geater, Sarayut
ÖZGÜROĞLU, Mustafa
Zou, Wei
Sandler, Alan
Enquist, Ida
Metadata
Show full item record
Abstract
BackgroundThe efficacy and safety of the anti-programmed death ligand 1 (PD-L1) monoclonal antibody atezolizumab, as compared with those of platinum-based chemotherapy, as first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC) with PD-L1 expression are not known.
URI
http://hdl.handle.net/20.500.12627/3223
https://doi.org/10.1056/nejmoa1917346
Collections